OSLO, Norway, Nov. 28, 2018 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage biotechnology company developing
immune activators to target hard-to-treat solid tumors, announces
that members of its senior management will present at the following
life sciences and investor conferences:
Date: 29 November 2018
Venue: Nordic-American Life Science Conference, NYC, US
Keynote panel: The Allure and Challenges of Nordic
Healthcare Acquisitions and Partnerships
Time: 12:30 PM EST
Presentation:
Time: 3:00 PM
EST
Presenter: Torbjørn Furuseth, CFO
Date: 5 December 2018
Venue: 4th Annual Oncolytic Virotherapy Summit, Boston, USA
Presentation:
Time: 12:30 PM EST
Presenter: Erik Digman Wiklund,
CBO
Panel Discussion: Comparing and Contrasting Virus
Types
Time: 4:30 PM EST
The 4th Oncolytic Virotherapy Summit is the leading
international conference in the oncolytic virotherapy field for
biotech and pharma drug developers to gain scientific and clinical
trial updates. In the above mentioned panel discussion,
Erik Digman Wiklund, CBO of
Targovax, will, together with William
Jia, CSO of Virogin, Robert
Coffin, CEO of Replimune and Stephen
Russell, CEO of Vyriad discuss wild-type and newer
generations viruses expressing immune stimulatory payloads or tumor
antigens.
The presentations will be available to download at
www.targovax.com following these events.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas
Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting
(International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/targovax/r/targovax-is-invited-to-present-at-upcoming-investor-and-industry-conferences,c2684662
View original
content:http://www.prnewswire.com/news-releases/targovax-is-invited-to-present-at-upcoming-investor-and-industry-conferences-300756622.html
SOURCE Targovax